Watermark Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Watermark Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$10K	Buy	+112	New	+$10.7K	﹤0.01%	163

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Watermark Asset Management's BMRN Position: Q4 2018 in Review

Watermark Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2018: 112 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #163 among its holdings.

472 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Watermark Asset Management held 112 shares of BioMarin Pharmaceuticals worth $10K as of Q4 2018.
BioMarin Pharmaceuticals was a new Watermark Asset Management position in Q4 2018.
BioMarin Pharmaceuticals made up ﹤0.01% of Watermark Asset Management's portfolio in Q4 2018, its #163 holding.
472 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Watermark Asset Management's 13F filing for Q4 2018, filed 14 Jan 2019.